The NCI60 human tumour cell line anticancer drug screen.
The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.
Shoemaker
Robert H
RH
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, USA. shoemaker@dtpax2.ncifcrf.gov
D000818:Animals; D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor / Q000266:history*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009316:National Institutes of Health (U.S.) / Q000266:history / Q000458:organization & administration; D014407:Tumor Cells, Cultured; D014481:United States
D000970:Antineoplastic Agents